MARVEL third plenary meeting!

Screenshot of MARVEL's third virtual plenary

The latest plenary meeting of MARVEL took place on November 18-19, 2021 in a hybrid format with almost half of the partners meeting face2face in Athens Greece and the other half virtually. Many thanks to our partner ITML for organizing everything regarding the face2face part.

The meeting started with the Project Coordinator giving an overview of the project progress, highlighting the consortium’s achievements but also addressing the project risks, encouraging the discussion for their mitigation.

The meeting proceeded traditionally with updates regarding the Data Management Plan, Quality Assurance and Risk Management as well as Innovation Management. Presentations of the progress per Work Package followed up and the second day was mostly dedicated on the hands-on work related to the release of the upcoming Minimum Viable Product (MVP) for MARVEL focusing on the pilot case led by Greenroads Malta.The MVP is planned to be released in M12 of the project, that being end of December 2021, so… stay tuned!

Living in the era of a pandemic, the fact that a few partners were allowed to attend the meeting physically was great for the bonding of the team and getting a few things done faster and easier. It was proven for one more time that although technology is allowing us to collaborate remotely with no issues, face2face meetings are irreplaceable for team building and in some cases speed.

For more direct updates follow us on LinkedIn and on Twitter. For regular updates including a collection of news and relevant information sign up on our Newsletter here.



[email-subscribers-form id="1"]

Key Facts

  • Project Coordinator: Dr. Sotiris Ioannidis
  • Institution: Foundation for Research and Technology Hellas (FORTH)
  • E-mail: marvel-info{at} 
  • Start: 01.01.2021
  • Duration: 36 months
  • Participating Organisations: 17
  • Number of countries: 12

Get Connected



This project has received funding from the European Union’s Horizon 2020 Research and Innovation program under grant agreement No 957337. The website reflects only the view of the author(s) and the Commission is not responsible for any use that may be made of the information it contains.